Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LYPLA2 pseudogene 1 (LYPLA2P1), also known as dJ570F3.6 or APT, is annotated as a pseudogene. Pseudogenes are genomic sequences that resemble known genes but are generally considered non-functional due to the accumulation of disabling mutations or lack of expression[1]. Specifically, LYPLA2P1 is related to the functional LYPLA2 gene, which encodes an enzyme (acyl-protein thioesterase 2) involved in deacylation of S-acylated proteins and lysophospholipase activity[2][7]. LYPLA2P1 has not been shown to be protein-coding, does not act as a receptor, enzyme, or other drug target, and is not referenced in therapeutic or disease-related literature as a functional molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LYPLA2 pseudogene 1 (LYPLA2P1).